{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:17:36Z","timestamp":1778523456123,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["TI081729-01"],"award-info":[{"award-number":["TI081729-01"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["1H79TI083288"],"award-info":[{"award-number":["1H79TI083288"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004925","name":"Texas Health and Human Services Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.japh.2024.102062","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T12:20:28Z","timestamp":1709295628000},"page":"102062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patients\u2019 willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States"],"prefix":"10.1016","volume":"64","author":[{"given":"Yinan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby M.","family":"Coggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Cirildo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandler","family":"Gandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7500","authenticated-orcid":false,"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.japh.2024.102062_bib1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/pme.12760","article-title":"Acute pain medicine in the United States: a status report","volume":"16","author":"Tighe","year":"2015","journal-title":"Pain Med"},{"issue":"390","key":"10.1016\/j.japh.2024.102062_bib2","first-page":"1","article-title":"Chronic pain and high-impact chronic pain among U.S. adults, 2019","author":"Zelaya","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.japh.2024.102062_bib3","series-title":"Pain Management Best Practices Inter-agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations","author":"United States Department of Health and Human Services","year":"2019"},{"key":"10.1016\/j.japh.2024.102062_bib5","author":"Hedegaard"},{"issue":"8","key":"10.1016\/j.japh.2024.102062_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2663","article-title":"Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010\u20132018","volume":"3","author":"Peet","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.japh.2024.102062_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5388","article-title":"Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017","volume":"2","author":"Guadamuz","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2024.102062_bib11","first-page":"13","article-title":"Considering the potential benefits of over-the-counter naloxone","volume":"10","author":"Evoy","year":"2021","journal-title":"Integr Pharm Res Pract"},{"issue":"6","key":"10.1016\/j.japh.2024.102062_bib13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1050","article-title":"The president\u2019s commission on combating drug addiction and the opioid crisis: origins and recommendations","volume":"103","author":"Madras","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.japh.2024.102062_bib15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.2018.4867","article-title":"Increasing naloxone awareness and use: the role of health care practitioners","volume":"319","author":"Adams","year":"2018","journal-title":"JAMA"},{"issue":"2S","key":"10.1016\/j.japh.2024.102062_bib18","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.japh.2016.11.007","article-title":"State legal innovations to encourage naloxone dispensing","volume":"57","author":"Davis","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2024.102062_bib19","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00304-2","article-title":"Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study","volume":"7","author":"Irvine","year":"2022","journal-title":"Lancet Public Health"},{"issue":"10","key":"10.1016\/j.japh.2024.102062_bib20","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1007\/s11606-021-06662-3","article-title":"Concurrent naloxone dispensing among individuals with high-risk opioid prescriptions, USA, 2015\u20132019","volume":"36","author":"Guy","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102062_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3209","article-title":"Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose","volume":"2","author":"Follman","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.japh.2024.102062_bib22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1186\/s12889-022-13741-5","article-title":"A\u00a0qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin","volume":"22","author":"Spector","year":"2022","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.japh.2024.102062_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/1475-6773.13125","article-title":"Will converting naloxone to over-the-counter status increase pharmacy sales?","volume":"54","author":"Murphy","year":"2019","journal-title":"Health Serv Res"},{"issue":"23","key":"10.1016\/j.japh.2024.102062_bib25","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1056\/NEJMp1609578","article-title":"The rising price of naloxone\u2014risks to efforts to stem overdose deaths","volume":"375","author":"Gupta","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2024.102062_bib27","first-page":"UT2014","article-title":"ESOMAR 28: 28 questions to help research buyers of online samples Provo","volume":"459","year":"2019"},{"issue":"3","key":"10.1016\/j.japh.2024.102062_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11606-016-3911-z","article-title":"Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain","volume":"32","author":"Behar","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"issue":"9","key":"10.1016\/j.japh.2024.102062_bib29","first-page":"730","article-title":"Naloxone counseling for harm reduction and patient engagement","volume":"49","author":"Han","year":"2017","journal-title":"Fam Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102062_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1370\/afm.1972","article-title":"Primary care patient experience with naloxone prescription","volume":"14","author":"Behar","year":"2016","journal-title":"Ann Fam Med"},{"issue":"3","key":"10.1016\/j.japh.2024.102062_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/pm\/pnx021","article-title":"Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids","volume":"19","author":"Nielsen","year":"2018","journal-title":"Pain Med"},{"issue":"3","key":"10.1016\/j.japh.2024.102062_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11606-016-3895-8","article-title":"Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain","volume":"32","author":"Mueller","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2024.102062_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12954-022-00687-5","article-title":"Intention to get naloxone among patients prescribed opioids for chronic pain","volume":"19","author":"Huang","year":"2022","journal-title":"Harm Reduct J"},{"issue":"17","key":"10.1016\/j.japh.2024.102062_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.18446","article-title":"New guidance aims to improve community access to naloxone","volume":"328","author":"Larkin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.japh.2024.102062_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12954-022-00700-x","article-title":"A\u00a0systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs","volume":"19","author":"Sajwani","year":"2022","journal-title":"Harm Reduct J"},{"issue":"6","key":"10.1016\/j.japh.2024.102062_bib37","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.japh.2022.07.008","article-title":"Naloxone accessibility without an outside prescription from US community pharmacies: a systematic review","volume":"62","author":"Lai","year":"2022","journal-title":"J.\u00a0Am. Pharm. Assoc. (2003)"},{"issue":"7","key":"10.1016\/j.japh.2024.102062_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40264-020-00923-6","article-title":"Rates and costs of dispensing naloxone to patients at high risk for opioid overdose in the United States, 2014\u20132018","volume":"43","author":"Barenie","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.japh.2024.102062_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106820","article-title":"Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018","volume":"153","author":"Dunphy","year":"2021","journal-title":"Prev Med"},{"issue":"2S","key":"10.1016\/j.japh.2024.102062_bib41","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J.\u00a0Am. Pharm. Assoc. (2003)"},{"key":"10.1016\/j.japh.2024.102062_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102827","article-title":"Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: a structural equation modeling approach","volume":"83","author":"Varisco","year":"2020","journal-title":"Int. J. Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2024.102062_bib43","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","article-title":"Risk factors for opioid-use disorder and overdose","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.japh.2024.102062_bib44","first-page":"369","article-title":"Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy","volume":"10","author":"Park","year":"2016","journal-title":"J\u00a0Addict Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:54:28Z","timestamp":1778522068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1544319124000827"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102062","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients\u2019 willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102062"}}